Heightened Dopaminergic Response to Amphetamine at the D 3 Dopamine Receptor in Methamphetamine Users.

Neuroimaging studies in stimulant use (eg, cocaine, methamphetamine) disorders show that diminished dopamine release by dopamine-elevating drugs is a potential marker of relapse and suggest that increasing dopamine at the D2/3 receptors may be therapeutically beneficial. In contrast, recent investigations indicate heightened D3 receptor levels in stimulant users prompting the view that D3 antagonism may help prevent relapse. Here we tested whether a 'blunted' response to amphetamine in methamphetamine (MA) users extends to D3 -rich brain areas. Fourteen MA users and 15 healthy controls completed two positron emission tomographic scans with a D3 -preferring probe [11 C]-(+)-PHNO at baseline and after amphetamine (0.4 mg/kg). Relative to healthy controls, MA users had greater decreases in [11 C]-(+)-PHNO binding (increased dopamine release) after amphetamine in D3 -rich substantia nigra (36 vs 20%, p=0.03) and globus pallidus (30 vs 17%, p=0.06), which correlated with self-reported 'drug wanting'. We did not observe a 'blunted' dopamine response to amphetamine in D2 -rich striatum; however, drug use severity was negatively associated with amphetamine-induced striatal changes in [11 C]-(+)-PHNO binding. Our study provides evidence that dopamine transmission in extrastriatal 'D3 -areas' is not blunted but rather increased in MA users. Together with our previous finding of elevated D3 receptor level in MA users, the current observation suggests that greater dopaminergic transmission at the D3 dopamine receptor may contribute to motivation to use drugs and argues in favor of D3 antagonism as a possible therapeutic tool to reduce craving and relapse in MA addiction.